NCT04626284 (DCDNRPHeart) is a NA clinical trial of Heart Transplantation in Heart Transplant Failure, sponsored by University of Nebraska.

Who is sponsoring NCT04626284?

NCT04626284 is sponsored by University of Nebraska.

What drugs are being tested in NCT04626284?

Interventions in NCT04626284: Heart Transplantation.

What condition does NCT04626284 study?

NCT04626284 studies Heart Transplant Failure, Determination of Death, Outcomes Research, Death.

Is NCT04626284 still recruiting?

NCT04626284 is currently completed. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT04626284: DCDNRPHeart

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Effectiveness of NRP for DCD Heart Transplantation

Completed NA Last updated 28 September 2023

What this trial tests

NA trial testing Heart Transplantation in Heart Transplant Failure in 10 participants. Completed in 8 April 2022.

Timeline

3 January 2021

Primary endpoint
8 April 2022

8 April 2022

Quick facts

Lead sponsor	University of Nebraska
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	3 January 2021
Primary completion	8 April 2022
Estimated completion	8 April 2022
Sites	1 location across United States

Drugs / interventions tested

Heart Transplantation

Conditions studied

Heart Transplant Failure — all drugs for Heart Transplant Failure →
Determination of Death — all drugs for Determination of Death →
Outcomes Research — all drugs for Outcomes Research →
Death — all drugs for Death →

Sponsor

University of Nebraska

Who can join

19 and older, any sex, with Heart Transplant Failure or Determination of Death. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, observational, pilot trial to evaluate the feasibility of heart transplantation using normothermic regional perfusion (NRP) donation after donor circulatory death (DCD). Normothermic regional perfusion utilizes Extracorporeal Membrane Oxygenation (ECMO) or cardiopulmonary bypass to reperfuse the heart and other organs in situ after isolation and ligation of the cerebral vessels. In situ resuscitation of the heart has the added advantage of allowing full hemodynamic and echocardiographic assessment of the donor heart prior to final acceptance for transplantation without the imminent danger of ongoing warm ischemia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cardiac function unchanged following reanimation with normothermic regional perfusion in donation after circulatory death.
Markin NW, Chacon MM, Castleberry AW, Fristoe L, et al · · 2022 · cited 3× · PMID 36276687 · DOI 10.1016/j.xjtc.2022.07.018

Verify or expand the search:

Other recruiting trials for Heart Transplant Failure

Currently open trials in the same condition.

NCT06428097 — Levothyroxine Supplementation for Heart Transplant Recipients · Phase 1 · recruiting
NCT05321706 — DAPAgliflozin for Renal Protection in Heart Transplant Recipients · Phase 3 · recruiting
NCT04180085 — Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at R · Phase 2 · recruiting

Other University of Nebraska trials

Trials by the same sponsor.

NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04626284 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04626284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing